NIKKEI 225
38,229.11 +155.13 (+0.41%) HANG SENG
18,931.60 +393.79 (+2.12%) CRUDE OIL
79.89 +0.63 (+0.79%) GOLD FUTURES
2,368.10 +27.80 (+1.19%) DOW
39,387.76 +331.36 (+0.85%) Bitcoin GBP
50,128.86 +928.99 (+1.89%)
Curis, Inc. (CRIS)
| Previous close | 16.35 |
| Open | 16.93 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 16.30 - 16.93 |
| 52-week range | 0.38 - 17.49 |
| Volume | |
| Avg. volume | 25,837 |
| Market cap | 97.311M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -8.96 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 24.75 |
Insider MonkeyCuris, Inc. (NASDAQ:CRIS) Q1 2024 Earnings Call Transcript
Curis, Inc. (NASDAQ:CRIS) Q1 2024 Earnings Call Transcript May 7, 2024 Curis, Inc. misses on earnings expectations. Reported EPS is $-2.0534 EPS, expectations were $-1.94. CRIS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and […]
PR NewswireCuris Provides First Quarter 2024 Business Update
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the first quarter ended March 31, 2024.
- PR Newswire
Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024
Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will release its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:00 a.m. ET. Management will host a conference call on the same day at 8:30 a.m. ET.
